Cerebral oxygen transport failure?: decreasing hemoglobin and hematocrit levels after ischemic stroke predict poor outcome and mortality: STroke: RelevAnt Impact of hemoGlobin, Hematocrit and Transfusion (STRAIGHT)--an observational study.

Optical characterization of two-layered turbid media for non-invasive, absolute oximetry in cerebral and extracerebral tissue. PLoS One (2013) 0.86

Sex differences and hemoglobin levels in relation to stroke outcomes. Neurology (2013) 0.82

Loss of Penumbra by Impaired Oxygen Supply? Decreasing Hemoglobin Levels Predict Infarct Growth after Acute Ischemic Stroke: Stroke: Relevant Impact of Hemoglobin, Hematocrit and Transfusion (STRAIGHT) - An Observational Study. Cerebrovasc Dis Extra (2012) 0.78

Red blood cell transfusion in the neurological ICU. Neurotherapeutics (2012) 0.77

Serum erythropoietin and outcome after ischaemic stroke: a prospective study. BMJ Open (2016) 0.75

Impact of Hemoglobin Levels and Anemia on Mortality in Acute Stroke: Analysis of UK Regional Registry Data, Systematic Review, and Meta-Analysis. J Am Heart Assoc (2016) 0.75

The role of additional computed tomography in the decision-making process on the secondary prevention in patients after systemic cerebral thrombolysis. Ther Clin Risk Manag (2015) 0.75

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25

Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet (2010) 12.21

Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet (2007) 10.74

Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med (2015) 9.58

Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med (2005) 9.58

Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol (2007) 6.15

Idarucizumab for Dabigatran Reversal. N Engl J Med (2015) 5.91

Hemicraniectomy in older patients with extensive middle-cerebral-artery stroke. N Engl J Med (2014) 5.79

Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med (2008) 5.77

European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace (2013) 5.16

Thrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive. BMJ (2010) 4.74

Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet (2008) 4.14

Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation (2012) 4.10

Short-term outcome after stenting versus endarterectomy for symptomatic carotid stenosis: a preplanned meta-analysis of individual patient data. Lancet (2010) 4.07

Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol (2008) 3.98

Results of the Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) study to treat symptomatic stenoses at 2 years: a multinational, prospective, randomised trial. Lancet Neurol (2008) 3.91

Predicting long-term outcome after acute ischemic stroke: a simple index works in patients from controlled clinical trials. Stroke (2008) 3.21

Stroke magnetic resonance imaging is accurate in hyperacute intracerebral hemorrhage: a multicenter study on the validity of stroke imaging. Stroke (2004) 3.07

Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke (2006) 3.03

Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol (2012) 2.77

Continuous stroke unit electrocardiographic monitoring versus 24-hour Holter electrocardiography for detection of paroxysmal atrial fibrillation after stroke. Stroke (2012) 2.64

Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol (2009) 2.64

Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol (2007) 2.56

Decompressive Surgery for the Treatment of Malignant Infarction of the Middle Cerebral Artery (DESTINY): a randomized, controlled trial. Stroke (2007) 2.56

Clinical and angiographic risk factors for stroke and death within 30 days after carotid endarterectomy and stent-protected angioplasty: a subanalysis of the SPACE study. Lancet Neurol (2008) 2.53

EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J (2013) 2.52

Recommendations on angiographic revascularization grading standards for acute ischemic stroke: a consensus statement. Stroke (2013) 2.50

Safety of thrombolysis in stroke mimics: results from a multicenter cohort study. Stroke (2013) 2.44

The stroke-thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic stroke. Stroke (2006) 2.43

Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke. Stroke (2003) 2.42

MRI versus CT-based thrombolysis treatment within and beyond the 3 h time window after stroke onset: a cohort study. Lancet Neurol (2006) 2.42

Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace (2015) 2.35

Comparison of CT and CT angiography source images with diffusion-weighted imaging in patients with acute stroke within 6 hours after onset. Stroke (2002) 2.33

An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J (2007) 2.31

Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation (2010) 2.27

Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke (2004) 2.24

Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST). Stroke (2008) 2.24

Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). J Am Coll Cardiol (2013) 2.17

Endovascular stroke therapy: tirofiban is associated with risk of fatal intracerebral hemorrhage and poor outcome. Stroke (2013) 2.11

Surgical decompression of patients with large middle cerebral artery infarcts is effective. Stroke (2003) 1.98

Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS One (2013) 1.97

Recommendations for the management of intracranial haemorrhage - part I: spontaneous intracerebral haemorrhage. The European Stroke Initiative Writing Committee and the Writing Committee for the EUSI Executive Committee. Cerebrovasc Dis (2006) 1.91

Imaging-based decision making in thrombolytic therapy for ischemic stroke: present status. Stroke (2003) 1.90

Stroke MRI in intracerebral hemorrhage: is there a perihemorrhagic penumbra? Stroke (2003) 1.90

Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke (2007) 1.90

Determinants of intracerebral hemorrhage growth: an exploratory analysis. Stroke (2007) 1.90

Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. J Clin Oncol (2004) 1.84

Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. Circulation (2009) 1.77

Point-of-care international normalized ratio testing accelerates thrombolysis in patients with acute ischemic stroke using oral anticoagulants. Stroke (2009) 1.69

Recurrent extracranial carotid artery vasospasms: report of 2 cases. Stroke (2006) 1.68

Herpes simplex virus encephalitis despite normal cell count in the cerebrospinal fluid. Crit Care Med (2012) 1.67

Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc (2007) 1.66

Acute stroke imaging research roadmap. Stroke (2008) 1.66

The main components of stroke unit care: results of a European expert survey. Cerebrovasc Dis (2007) 1.64

Baroreflex: a new therapeutic target in human stroke? Stroke (2009) 1.62

Shift analysis versus dichotomization of the modified Rankin scale outcome scores in the NINDS and ECASS-II trials. Stroke (2007) 1.62

Effectiveness and safety of transcranial laser therapy for acute ischemic stroke. Stroke (2009) 1.61

Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage. Stroke (2004) 1.60

Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke (2006) 1.60

Intra-arterial thrombolysis is the treatment of choice for basilar thrombosis: pro. Stroke (2006) 1.55

Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. Eur Heart J (2013) 1.53

Leukocyte count as an independent predictor of recurrent ischemic events. Stroke (2004) 1.50

Impact of statin use and lipid profile on symptomatic intracerebral haemorrhage, outcome and mortality after intravenous thrombolysis in acute stroke. Cerebrovasc Dis (2012) 1.48

Comparison of the European and Japanese guidelines for the management of ischemic stroke. Cerebrovasc Dis (2013) 1.47

Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J (2011) 1.47

Acute Stroke Imaging Research Roadmap II. Stroke (2013) 1.47

Autonomic shift and increased susceptibility to infections after acute intracerebral hemorrhage. Stroke (2011) 1.46

Stenting for carotid artery stenosis. Nat Clin Pract Neurol (2007) 1.44

Contemporary outcome measures in acute stroke research: choice of primary outcome measure. Stroke (2012) 1.43

Mismatch-based delayed thrombolysis: a meta-analysis. Stroke (2009) 1.41

Is the maximum dose of 90 mg alteplase sufficient for patients with ischemic stroke weighing >100 kg? Stroke (2011) 1.41

Acute stroke imaging research roadmap. AJNR Am J Neuroradiol (2008) 1.41

Comparison of ABC/2 estimation technique to computer-assisted planimetric analysis in warfarin-related intracerebral parenchymal hemorrhage. Stroke (2005) 1.41

Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost (2015) 1.36

Postprandial response of plasma ghrelin levels to various test meals in relation to food intake, plasma insulin, and glucose. J Clin Endocrinol Metab (2004) 1.35

The Virtual International Stroke Trials Archive. Stroke (2007) 1.34

Magnetic resonance imaging evidence of cytotoxic cerebral edema in acute mountain sickness. J Cereb Blood Flow Metab (2006) 1.34

Thromboembolic events with recombinant activated factor VII in spontaneous intracerebral hemorrhage: results from the Factor Seven for Acute Hemorrhagic Stroke (FAST) trial. Stroke (2009) 1.32

Outcome and symptomatic bleeding complications of intravenous thrombolysis within 6 hours in MRI-selected stroke patients: comparison of a German multicenter study with the pooled data of ATLANTIS, ECASS, and NINDS tPA trials. Stroke (2006) 1.31

Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol (2002) 1.30

Solitaire™ with the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) trial: protocol for a randomized, controlled, multicenter study comparing the Solitaire revascularization device with IV tPA with IV tPA alone in acute ischemic stroke. Int J Stroke (2015) 1.29

Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc (2013) 1.26

Predictors of early cardiac morbidity and mortality after ischemic stroke. Stroke (2007) 1.26

Contribution of obesity and abdominal fat mass to risk of stroke and transient ischemic attacks. Stroke (2008) 1.25

Improved prediction of poor outcome after thrombolysis using conservative definitions of symptomatic hemorrhage. Stroke (2011) 1.24

Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol (2013) 1.23